Acadia Pharmaceuticals
ACAD· Manufacturing· Fiscal year ends in December
No proxy on file names the CEO of Acadia Pharmaceuticals.
Executives9
See all- 1Thomas GarnerFY2023
- 2Catherine OwenNot disclosed
- 3Catherine Owen AdamsDirectorNot disclosed
- 4Elizabeth ThompsonDirectorNot disclosed
- 5Jennifer RhodesDirectorNot disclosed
- 6Mark C. SchneyerDirectorNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAcadia Pharmaceuticals paid its one named executive on file $0 in FY2023 (Dec).
| Name | |||
|---|---|---|---|
| Thomas Garner | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe FY2024 (Dec) proxy of Acadia Pharmaceuticals names 19 peer companies for pay. Among Acadia Pharmaceuticals and these peers, CEO pay was 7th highest of 9 and total shareholder return was the lowest of 9.
7th highest of 9in Acadia Pharmaceuticals and its pay peers, FY2024 (Dec) by CEO pay:
9th highest of 9in Acadia Pharmaceuticals and its pay peers, FY2024 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board5
See all- Laura A. BregeDirector · 17 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
- Edmund P. HarriganDirector · 10 yr on the boardIndependentAudit—Paid as an executive
- Julian C. BakerDirector · 10 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- James M. DalyDirector · 9 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Elizabeth A. GarofaloDirector · 5 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |